Bayer Diagnostics Launches Advia Centaur(R) CP Immunoassay System

Main Category: Medical Devices / Diagnostics
Article Date: 17 Dec 2005 - 0:00 PDT

email to a friend   printer friendly   opinions  

Bayer Diagnostics (a division of Bayer HealthCare) has launched its new ADVIA Centaur(R) CP Immunoassay System. The ADVIA Centaur CP, part of the ADVIA family of automated clinical laboratory solutions from Bayer Diagnostics, is a compact, benchtop, fully automated analytical system which enables hospital and reference laboratories to rapidly perform a wide variety of disease-specific tests which enhance the management of disease.

Following in the footsteps of the market-leading ADVIA Centaur(R) Immunoassay system, the ADVIA Centaur CP includes many unique productivity enhancement features. Additionally, it uses the same proven assay methodologies and reagent packs as the ADVIA Centaur. The complete menu of disease state assay groups currently available on the ADVIA Centaur, including cardiovascular, oncology, fertility, and infectious disease testing capabilities, will be available on the ADVIA Centaur CP.

The ADVIA Centaur CP, with its chemistry counterpart, the ADVIA(R) 1200 Clinical Chemistry System, working with Bayer's networking and data management solution, ADVIA CentraLink(R), delivers synergies of sample handling, connectivity and system functionality to provide a complete immunoassay and clinical chemistry solution. This enables the smaller lab to offer a complete testing service without costly sample splitting and result collation.

"The ADVIA Centaur CP is a key component of our strategy to better serve our customers by offering more analytical platforms, more assays and improved connectivity and integration," said Tony Bihl, President of Bayer Diagnostics. "Our objective at Bayer Healthcare is to be the preferred partner and provider of solutions, both to the high-end, high-volume, fully automated laboratory, and now, with the introduction of the ADVIA Centaur CP, to the mid-sized laboratory in the community hospital, IDN satellite or private facility."

"Market intelligence from UK customers and customers worldwide told us that what was needed was an immunoassay platform that packaged ADVIA Centaur Immunoassay System technology in a smaller footprint," says Fiona Howe, Senior Product Manager in the UK for Bayer's immunoassay and molecular diagnostic products. "Mid-size and speciality laboratories can now make improvements in productivity by consolidating testing onto the ADVIA Centaur CP which provides them with a single platform sized for their laboratory needs."

http://www.bayerdiag.com

• Additional
• References
• Citations